Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Robin Cornelissen, MD, PhD, on ZENITH20-4: Use of Poziotinib Under Study in HER2 Exon 20–Mutated NSCLC

Posted: Tuesday, September 28, 2021

Robin Cornelissen, MD, PhD, of Erasmus University in Rotterdam, talks about how new data on poziotinib, a novel tyrosine kinase inhibitor, may alter the treatment landscape for newly diagnosed patients with HER2 exon 20–mutated non–small cell lung cancer. The mutation is found in up to 4% of patients with NSCLC.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.